Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review
Fig 6
Hazard ratios (HRs) of overall median survival (OS) comparing monotherapy and combination therapy trials, arranged by trial initiation date (publication date shown).
Asterisks indicate significant survival benefit according to prespecified statistical thresholds. RCC = renal cell carcinoma; HCC = hepatocellular carcinoma; NSCLC = non-small-cell lung carcinoma. Per-trial data are available in our supplementary materials (see S1 Data).
doi: https://doi.org/10.1371/journal.pbio.2000487.g006